{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T13:51:47Z","timestamp":1793022707657,"version":"4.5.0"},"reference-count":31,"publisher":"American Chemical Society (ACS)","issue":"41","license":[{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"funder":[{"name":"Anhui Provincial University Scientific Research Project","award":["2022AH051162"],"award-info":[{"award-number":["2022AH051162"]}]},{"name":"Anhui University Collaborative Innovation Project","award":["GXXT-2023-074"],"award-info":[{"award-number":["GXXT-2023-074"]}],"id":[{"id":"https:\/\/ror.org\/05th6yx34","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Cultivation Project for Qihuang Scholar Seed Candidates in Anhui Province","award":["Wan Zhong Yi Yao Mi [2025]  9"],"award-info":[{"award-number":["Wan Zhong Yi Yao Mi [2025]  9"]}]},{"name":"National Clinical Collaboration Project of Traditional Chinese and Western Medicine for Major and Difficult Diseases","award":["Guo Zhong Yi Yao Zong Jie He Fa [2024]  3"],"award-info":[{"award-number":["Guo Zhong Yi Yao Zong Jie He Fa [2024]  3"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Head and neck squamous cell carcinoma (HNSCC) remains difficult to treat, and conventional chemotherapy has limited efficacy and substantial toxicity. We developed a VYQFF peptide-modified brucine liposome (Bru-VYQFF-Lip) and characterized its particle size, zeta potential, polydispersity, encapsulation efficiency, and drug loading. Bru-VYQFF-Lip showed greater uptake in Trop2-high HSC3 cells than in HOK cells and inhibited HNSCC-cell proliferation, migration, and invasion while promoting apoptosis. After intratumoral administration, the VYQFF-modified formulation showed greater local fluorescence retention than the NHS-bearing, non-peptide comparator; this experiment does not establish systemic tumor targeting or direct Trop2-specific recognition. Bru-VYQFF-Lip also suppressed tumor growth in a nude-mouse xenograft model. Terminal serum chemistry and organ histology did not reveal overt hepatorenal or histopathological injury, although the safety assessment was limited by the absence of complete longitudinal and hematological evaluation. Bioinformatic and experimental analyses identified INHBA as a candidate mediator associated with poor prognosis. Mechanistic experiments were consistent with suppression of the INHBA\/TGF-\u03b2\/Smad axis and epithelial-mesenchymal transition. These findings support further evaluation of VYQFF-functionalized brucine liposomes, including physicochemically matched controls, receptor-blocking studies, systemic biodistribution experiments, and comprehensive toxicology.<\/jats:p>","DOI":"10.1021\/acsami.6c15023","type":"journal-article","created":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T20:01:56Z","timestamp":1791835316000},"page":"55946-55961","source":"Crossref","is-referenced-by-count":0,"title":["VYQFF Peptide-Modified Brucine Liposomes: Antitumor Activity in Head and Neck Squamous Cell Carcinoma and Mechanistic Insights"],"prefix":"10.1021","volume":"18","author":[{"given":"Rixin","family":"Su","sequence":"first","affiliation":[{"name":"The First Affiliated Hospital of Anhui Medical University , , , ,","place":["Hefei, Anhui, China, 230022"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runjing","family":"Li","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Anhui Medical University , , , ,","place":["Hefei, Anhui, China, 230022"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaorui","family":"Wu","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Anhui Medical University , , , ,","place":["Hefei, Anhui, China, 230022"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Xiong","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Anhui Medical University , , , ,","place":["Hefei, Anhui, China, 230022"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Jin","sequence":"additional","affiliation":[{"name":"Anhui University of Chinese Medicine , , ,","place":["Hefei, Anhui, China, 230012"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueling","family":"Zhang","sequence":"additional","affiliation":[{"name":"Anhui University of Chinese Medicine , , ,","place":["Hefei, Anhui, China, 230012"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Banglong","family":"Song","sequence":"additional","affiliation":[{"name":"The First Hospital of the University of Science and Technology of China , , , ,","place":["Hefei, Anhui, China, 230001"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[{"name":"The First Hospital of the University of Science and Technology of China , , , ,","place":["Hefei, Anhui, China, 230001"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8900-3595","authenticated-orcid":true,"given":"Ping","family":"Li","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Anhui Medical University , , , ,","place":["Hefei, Anhui, China, 230022"]},{"name":"Anhui Medical University , , , ,","place":["Hefei, Anhui, China, 230032"]},{"name":"Anhui University of Chinese Medicine , , ,","place":["Hefei, Anhui, China, 230012"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,10,12]]},"reference":[{"issue":"3","key":"2026102609063059700_cit1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2020","journal-title":"CA Cancer J. Clin."},{"issue":"10","key":"2026102609063059700_cit2","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1097\/COC.0000000000001204","article-title":"Research Progress of SBRT Combined With Immunotherapy in Locally Advanced Head and Neck Cancer","volume":"48","author":"Feng","year":"2025","journal-title":"Am. J. Clin. Oncol."},{"key":"2026102609063059700_cit3","doi-asserted-by":"publisher","DOI":"10.1016\/j.archoralbio.2021.105087","article-title":"Propolis reduces the stemness of head and neck squamous cell carcinoma","volume":"125","author":"Nor","year":"2021","journal-title":"Arch. Oral Biol."},{"key":"2026102609063059700_cit4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2022.114450","article-title":"Design, synthesis and biological evaluation of new parbendazole derivatives for the treatment of HNSCC","volume":"238","author":"Liang","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"2026102609063059700_cit5","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00377","article-title":"Brucine: A Review of Phytochemistry, Pharmacology, and Toxicology","volume":"11","author":"Lu","year":"2020","journal-title":"Front. Pharmacol."},{"key":"2026102609063059700_cit6","doi-asserted-by":"publisher","first-page":"6945","DOI":"10.2147\/IJN.S467876","article-title":"Albumin Nanoparticle-Based Drug Delivery Systems","volume":"19","author":"Qu","year":"2024","journal-title":"Int. J. Nanomedicine"},{"issue":"2","key":"2026102609063059700_cit7","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.ijpharm.2008.08.005","article-title":"Liposomal nanomedicines as anticancer therapeutics: beyond targeting tumor cells","volume":"364","author":"Schiffelers","year":"2008","journal-title":"Int. J. Pharm."},{"key":"2026102609063059700_cit8","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2021.113851","article-title":"Liposome composition in drug delivery design, synthesis, characterization, and clinical application","volume":"176","author":"Large","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"2026102609063059700_cit9","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.jconrel.2018.11.004","article-title":"Peptide-based targeted therapeutics: Focus on cancer treatment","volume":"292","author":"Araste","year":"2018","journal-title":"J. Control. Release"},{"key":"2026102609063059700_cit10","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfb.2021.111623","article-title":"Integrin alpha(v)beta(3)-targeted liposomal drug delivery system for enhanced lung cancer therapy","volume":"201","author":"Fu","year":"2021","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"2026102609063059700_cit11","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.jconrel.2016.10.030","article-title":"Hyperthermia-triggered drug delivery from iRGD-modified temperature-sensitive liposomes enhances the anti-tumor efficacy using high intensity focused ultrasound","volume":"243","author":"Deng","year":"2016","journal-title":"J. Control. Release"},{"issue":"29","key":"2026102609063059700_cit12","doi-asserted-by":"publisher","first-page":"4688","DOI":"10.1200\/JCO.23.01207","article-title":"Targeting Trop-2 as a Cancer Driver","volume":"41","author":"Guerra","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"2026102609063059700_cit13","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15061744","article-title":"Overview of Trop-2 in Cancer: From Pre-Clinical Studies to Future Directions in Clinical Settings","volume":"15","author":"Lombardi","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"3","key":"2026102609063059700_cit14","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.3390\/curroncol31030099","article-title":"ITGAV Promotes the Progression of Head and Neck Squamous Cell Carcinoma","volume":"31","author":"Xu","year":"2024","journal-title":"Curr. Oncol."},{"issue":"1","key":"2026102609063059700_cit15","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-00224-3","article-title":"Head and neck squamous cell carcinoma","volume":"6","author":"Johnson","year":"2020","journal-title":"Nat. Rev. Dis. Primers."},{"issue":"3","key":"2026102609063059700_cit16","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1517\/14656566.2011.523698","article-title":"Pharmacotherapy for squamous-cell carcinoma of the head and neck","volume":"12","author":"Papaspyrou","year":"2011","journal-title":"Expert Opin. Pharmacother."},{"issue":"9","key":"2026102609063059700_cit17","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1080\/14656566.2016.1183647","article-title":"Afatinib in squamous cell carcinoma of the head and neck","volume":"17","author":"Specenier","year":"2016","journal-title":"Expert Opin. Pharmacother."},{"issue":"1","key":"2026102609063059700_cit18","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-024-00633-6","article-title":"Trop2-targeted therapy in breast cancer","volume":"12","author":"Hu","year":"2024","journal-title":"Biomark. Res."},{"issue":"1","key":"2026102609063059700_cit19","first-page":"73","article-title":"The role of Trop2 in prostate cancer: an oncogene, biomarker, and therapeutic target","volume":"9","author":"Shen","year":"2021","journal-title":"Am. J. Clin. Exp. Urol."},{"issue":"5","key":"2026102609063059700_cit20","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1158\/1078-0432.CCR-24-2523","article-title":"Sacituzumab Govitecan in Patients with Relapsed\/Refractory Advanced Head and Neck Squamous Cell Carcinoma: Results from the Phase II TROPiCS-03 Basket Study","volume":"31","author":"Michel","year":"2025","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"2026102609063059700_cit21","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1002\/cbf.3573","article-title":"Inhibin, beta A regulates the transforming growth factor-beta pathway to promote malignant biological behaviour in colorectal cancer","volume":"39","author":"He","year":"2021","journal-title":"Cell Biochem. Funct."},{"issue":"2","key":"2026102609063059700_cit22","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.jobcr.2020.03.015","article-title":"Expression of transforming growth factor beta in oral submucous fibrosis","volume":"10","author":"Rai","year":"2020","journal-title":"J. Oral Biol. Craniofac Res."},{"issue":"12","key":"2026102609063059700_cit23","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1038\/onc.2012.171","article-title":"TGF-beta and NF-kappaB signal pathway cross-talk is mediated through TAK1 and SMAD7 in a subset of head and neck cancers","volume":"32","author":"Freudlsperger","year":"2013","journal-title":"Oncogene"},{"issue":"12","key":"2026102609063059700_cit24","doi-asserted-by":"publisher","first-page":"5299","DOI":"10.21873\/anticanres.16733","article-title":"Potential Roles of Activin in Head and Neck Squamous Cell Carcinoma Progression and Mortality","volume":"43","author":"Buryska","year":"2023","journal-title":"Anticancer Res."},{"issue":"6","key":"2026102609063059700_cit25","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.3892\/or.18.6.1489","article-title":"Identification of molecular targets in head and neck squamous cell carcinomas based on genome-wide gene expression profiling","volume":"18","author":"Shimizu","year":"2007","journal-title":"Oncol. Rep."},{"issue":"1","key":"2026102609063059700_cit26","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-50865-y","article-title":"Expression and gene regulation network of INHBA in Head and neck squamous cell carcinoma based on data mining","volume":"9","author":"Wu","year":"2019","journal-title":"Sci. Rep."},{"issue":"24","key":"2026102609063059700_cit27","doi-asserted-by":"publisher","first-page":"7140","DOI":"10.1158\/0008-5472.CAN-16-1188","article-title":"Dysregulation of RUNX2\/Activin-A Axis upon miR-376c Downregulation Promotes Lymph Node Metastasis in Head and Neck Squamous Cell Carcinoma","volume":"76","author":"Chang","year":"2016","journal-title":"Cancer Res."},{"issue":"1","key":"2026102609063059700_cit28","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s12943-025-02290-1","article-title":"EGFR-mediated local invasiveness and response to Cetuximab in head and neck cancer","volume":"24","author":"Zhou","year":"2025","journal-title":"Mol. Cancer"},{"issue":"1","key":"2026102609063059700_cit29","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01846-3","article-title":"Identification of multidrug chemoresistant genes in head and neck squamous cell carcinoma cells","volume":"22","author":"Khera","year":"2023","journal-title":"Mol. Cancer"},{"key":"2026102609063059700_cit30","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2020.576566","article-title":"Systematic Profiling of Immune Risk Model to Predict Survival and Immunotherapy Response in Head and Neck Squamous Cell Carcinoma","volume":"11","author":"Liu","year":"2020","journal-title":"Front. Genet."},{"key":"2026102609063059700_cit31","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2023.101862","article-title":"Multi-omics comprehensive analyses of programmed cell death patterns to regulate the immune characteristics of head and neck squamous cell carcinoma","volume":"41","author":"Jin","year":"2024","journal-title":"Transl. Oncol."}],"container-title":["ACS Applied Materials &amp; Interfaces"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acsami.6c15023","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/aamick\/article-pdf\/18\/41\/55946\/68825722\/am-2026-15023z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/aamick\/article-pdf\/18\/41\/55946\/68825722\/am-2026-15023z.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T13:30:14Z","timestamp":1793021414000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/aamick\/article\/18\/41\/55946\/5449303\/VYQFF-Peptide-Modified-Brucine-Liposomes-Antitumor"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,12]]},"references-count":31,"journal-issue":{"issue":"41","published-online":{"date-parts":[[2026,10,12]]},"published-print":{"date-parts":[[2026,10,21]]}},"URL":"https:\/\/doi.org\/10.1021\/acsami.6c15023","relation":{},"ISSN":["1944-8244","1944-8252"],"issn-type":[{"value":"1944-8244","type":"print"},{"value":"1944-8252","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,12]]}}}